FDA refuses to review Moderna’s mRNA flu vaccine
(Ars Technica) – In a news release late Tuesday, Moderna said it was blindsided by the FDA’s refusal, which the FDA cited as being due to the design of the company’s Phase 3 trial for its mRNA flu vaccine, dubbed … Read More
